Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Increased Level of The Plasminogen Activator Inhibitor Type-1 is Associated with Severity of NAFLD

Journal of Biomedicine and Translational Research · Vol. 9 No. 2 (2023) · hlm. 47–54

DOI
10.14710/jbtr.v9i2.16293
ISSN
2503-2178
Terbit
2023-08-31
Penerbit
Faculty of Medicine, Universitas Diponegoro
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-sa/4.0

Abstrak

Background: Non-Alcoholic Fatty Liver Disease (NAFLD) has been the most common cause of chronic liver disease worldwide. In NAFLD, elevated Plasminogen Activator Inhibitor-1 (PAI-1) is associated with risk factors for thrombosis and hypercoagulable state.Objective: This study explored the relationship between NAFLD as an independent factor for increasing PAI-1 in the presence of metabolic syndrome and insulin resistance.Methods: This observational study used a cross-sectional design with 80 subjects including 40 patients with NAFLD and 40 without NAFLD at dr. Kariadi Semarang who met the inclusion and exclusion criteria. Measurement of plasma PAI-1 levels was done using ELISA method.Results: A total of 80 patients were included. In the case group, based on abdominal ultrasound, NAFLD was mostly found in the mild category (86%), while the rest were moderate (10%), and severe (4%). Only 25% were found in the Simple Steatosis category, and 75% were suspected of having NASH (NAS = 3-4) and NASH (NAS > 5). There was a significant difference between plasma PAI-1 level and the incidence of NAFLD (p = 0.011). The mean PAI-1 level between the three NAFLD severity categories also shown a significant difference (p = 0.032).Conclusion: There is an increase in PAI-1 levels in patients with NAFLD. PAI-1 levels have an independent effect on the degree of liver fibrosis in patients with NAFLD.

Kata kunci

Jaringan kolaborasi para penulis

25 penulis · 76 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Diponegoro University
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Cecilia Oktaria PermatadewiDiponegoro University5
Hesti Triwahyu HutamiDiponegoro University5
Heru PrabowoDiponegoro University4
Tri Ferry RachmatullahDiponegoro University1
Charles LimantoroDiponegoro University1
Fransisca Yustika Dewi SiahaanDiponegoro University1
Khristophorus Heri Nugroho Hario SenoDiponegoro University1
Rakhma Yanti HellmiDiponegoro University1
Etika Ratna NoerDiponegoro University1
Adriyan PramonoDiponegoro University1
R.A. KusumaDiponegoro University1
Choirun NissaDiponegoro University1
Endang MahatiDiponegoro University1
Nani MaharaniDiponegoro University1
Sultana MH FaradzDiponegoro University1
Rayvita AN MeagratiaDiponegoro University1
Ferdy Kurniawan CayamiDiponegoro University1
Udin BahrudinDiponegoro University1
Wiwik LestariDiponegoro University1
Siti Fatimah MuisDiponegoro University1
Risky Ika RianiDiponegoro University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ejournal2.undip.ac.id/index.php/jbtr/oai, pertama di-harvest 9 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Increased Level of The Plasminogen Activator Inhibitor Type-1 is Associated with Severity of NAFLD</dc:title>
	<dc:creator>Indiarso, Didik</dc:creator>
	<dc:creator>Prasetyo, Agung</dc:creator>
	<dc:creator>Hirlan, Hirlan</dc:creator>
	<dc:creator>Purnomo, Hery Djagat</dc:creator>
	<dc:subject xml:lang="en-US">NAFLD; NASH; PAI-1; liver fibrosis</dc:subject>
	<dc:description xml:lang="en-US">Background: Non-Alcoholic Fatty Liver Disease (NAFLD) has been the most common cause of chronic liver disease worldwide. In NAFLD, elevated Plasminogen Activator Inhibitor-1 (PAI-1) is associated with risk factors for thrombosis and hypercoagulable state.Objective: This study explored the relationship between NAFLD as an independent factor for increasing PAI-1 in the presence of metabolic syndrome and insulin resistance.Methods: This observational study used a cross-sectional design with 80 subjects including 40 patients with NAFLD and 40 without NAFLD at dr. Kariadi Semarang who met the inclusion and exclusion criteria. Measurement of plasma PAI-1 levels was done using ELISA method.Results: A total of 80 patients were included. In the case group, based on abdominal ultrasound, NAFLD was mostly found in the mild category (86%), while the rest were moderate (10%), and severe (4%). Only 25% were found in the Simple Steatosis category, and 75% were suspected of having NASH (NAS = 3-4) and NASH (NAS &gt; 5). There was a significant difference between plasma PAI-1 level and the incidence of NAFLD (p = 0.011). The mean PAI-1 level between the three NAFLD severity categories also shown a significant difference (p = 0.032).Conclusion: There is an increase in PAI-1 levels in patients with NAFLD. PAI-1 levels have an independent effect on the degree of liver fibrosis in patients with NAFLD.</dc:description>
	<dc:publisher xml:lang="en-US">Faculty of Medicine, Universitas Diponegoro</dc:publisher>
	<dc:date>2023-08-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ejournal2.undip.ac.id/index.php/jbtr/article/view/16293</dc:identifier>
	<dc:identifier>10.14710/jbtr.v9i2.16293</dc:identifier>
	<dc:source xml:lang="en-US">Journal of Biomedicine and Translational Research; Vol 9, No 2 (2023): August 2023; 47-54</dc:source>
	<dc:source>2503-2178</dc:source>
	<dc:source>10.14710/jbtr.v9i2</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/view/16293/9644</dc:relation>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/downloadSuppFile/16293/4016</dc:relation>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/downloadSuppFile/16293/4017</dc:relation>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/downloadSuppFile/16293/4018</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2023 Journal of Biomedicine and Translational Research</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by-sa/4.0</dc:rights>
</oai_dc:dc>